Anti-BCMA heavy chain-only antibodies

Heavy chain only antibodies targeting BCMA offer a promising solution for improving the treatment of B-cell disorders by providing high affinity and specificity, addressing the limitations of current therapies.

JP2025037879APending Publication Date: 2025-03-18TENEOBIO INC
7 Cites 0 Cited by

Patent Information

Application Number
JP2024197991
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2016-12-21
Filing Date
2024-11-13
Publication Date
2025-03-18

AI Technical Summary

Technical Problem

Current treatments for B-cell disorders characterized by BCMA expression, such as multiple myeloma, have limitations in efficacy and toxicity, necessitating the development of more effective therapeutic agents.

Method used

The development of heavy chain only antibodies (HCAbs) that specifically bind to human BCMA, utilizing CDR1, CDR2, and CDR3 sequences with high affinity and specificity, to target and eliminate BCMA-expressing cells.

Benefits of technology

These anti-BCMA HCAbs demonstrate strong binding affinity and specificity, potentially leading to enhanced therapeutic efficacy in treating B-cell disorders like multiple myeloma with reduced toxicity.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

To provide a human idiotypic heavy chain-only antibody that binds to human B-Cell maturation antigen (BCMA).SOLUTION: Anti-BCMA heavy chain-only antibodies (HCAb) and disclosed along with methods of making such antibodies, compositions including pharmaceutical compositions comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA. In one embodiment, the invention relates to a heavy chain-only antibody binding to human B-Cell Maturation Antigen (BCMA). The heavy chain-only antibody comprises a heavy chain variable region comprising: (a) a CDR1 having at least 95% sequence identity to any of specific sequences; and / or (b) a CDR2 having at least 95% sequence identity to any of the specific sequences different from the above; and / or (c) a CDR3 having at least 95% sequence identity to any of the specific sequences different from the above.SELECTED DRAWING: Figure 5
Need to check novelty before this filing date? Find Prior Art